Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
It is indicated for the treatment of adult patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：12
It is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH, WHO Group 1), which can improve exercise capacity, delay clinical deterioration, or b···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring PDGFRA exon 18 mutations, advanced systemic mas···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：9
It is indicated for the treatment of various immune-related diseases in adults and children aged 2 years and older, including rheumatoid arthritis, atopic dermatitis, alopecia area···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult patients and pediatric patients with a body weight of at least 14 kilog···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults and children aged 3 years and older, which can improve exercise tolerance and delay clinical de···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of hyperprolactinemia in adults, including conditions caused by idiopathic factors or pituitary adenomas.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：1
This product is indicated for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations (in combination with vemurafenib), as···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：10
For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in adults and children 1 year of age and older.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
It is indicated for the treatment of adult patients with primary biliary cholangitis who have an inadequate response to or intolerance of ursodeoxycholic acid.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：10
It is indicated for the treatment of unresectable or metastatic melanoma, colorectal cancer, and non-small cell lung cancer with BRAF V600E or V600K mutations, and must be used in ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：7
It is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection. This includes ···【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：612025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
